January 16, 2025

Study Questions Urokinase's Role in Minor Stroke Care

For minor stroke patients, urokinase showed no added benefit for 90-day outcomes but remained safe, TRUST trial reveals.

Conexiant

January 16, 2025

FDA Clears Phase 2 Trial: Lorundrostat for OSA-Hypertension

Mineralys Therapeutics receives FDA clearance for a phase II clinical trial investigating lorundrostat, an aldosterone synthase inhibitor, in patients with moderate-to-severe obstructive sleep apnea and hypertension.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

January 15, 2025

CMR-PCWP Correlates with Heart Failure Biomarkers

In HFrEF patients, cardiovascular magnetic resonance-estimated pulmonary capillary wedge pressure "correlates with clinical and ultrasound markers of congestion," demonstrates potential as a non-invasive alternative to traditional pressure measurements.

Conexiant

January 15, 2025

Trametinib Reduces Surgery, Mortality in Pediatric RAS-HCM

MEK inhibitors significantly lower mortality and surgical needs in children with RASopathy-associated hypertrophic cardiomyopathy.

Conexiant

January 15, 2025

Can Wearables Help Manage Moderate Sleep Apnea Without CPAP?

Researchers are conducting the Moore4Medical trial to evaluate whether an eHealth intervention, consisting of a wrist device and a mobile application, can effectively manage blood pressure, sleep quality, and physical activity levels in adult patients with moderate obstructive sleep apnea and hypertension.

Conexiant

January 14, 2025

Remnant Cholesterol as Biomarker for Endometriosis, Study

‘An increase of one unit in RC was linked to a 135% rise in the likelihood of developing endometriosis,’ positioning remnant cholesterol as a promising marker for risk assessment.

Conexiant

January 13, 2025

Transcatheter Valve Replacement: Key 1-Year Outcomes

Transcatheter tricuspid-valve replacement reduced tricuspid regurgitation to a level that is mild or less in 95% of patients, with associated improvements in quality of life, functional capacity, and survival compared to medical therapy.

Conexiant

January 13, 2025

Heart Age vs. CVD Risk in Care

Explore how heart age and short-term cardiovascular disease risk differ in guiding preventive care.

Conexiant